Kala pharmaceuticals, inc. (KALA)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15
Cash flows from operating activities:
Net loss

-94,347

-66,738

-42,211

-33,167

-16,682

Adjustments to reconcile net loss to cash used in operating activities:
Depreciation

843

352

287

297

330

Non-cash operating lease cost

1,773

603

-

-

-

Amortization of right-of-use assets

-

-

356

-

-

Change in fair value of warrant liability

-

-

1,844

-122

132

Loss of extinguishment of debt

-

-390

-

-

-

Amortization of debt discount and other non-cash interest

958

274

111

-

-

Amortization of debt discount and other non-cash interest

-

-

-

106

134

Write-off of deferred offering costs

-

-

-

1,789

-

Stock-based compensation

9,991

8,615

3,571

2,069

638

Loss on disposal of fixed asset

-

-

-

-

-19

Change in operating assets and liabilities:
Accounts receivable

11,563

-

-

-

-36

Prepaid expenses and other current assets

1,789

1,387

494

66

-34

Inventory

4,271

3,868

-

-

-

Accounts payable

-2,770

4,088

205

-343

911

Accrued expenses and other current liabilities

9,630

3,968

2,601

2,108

-605

Lease liabilities and other long-term liabilities

-1,175

-418

-368

-

-

Lease liabilities and other long-term liabilities

-

-

-361

-

-

Other long-term liabilities

-

-

-

-19

-36

Net cash used in operating activities

-92,720

-54,121

-34,098

-27,348

-15,089

Cash flows from investing activities:
Purchases of property and equipment

1,335

1,578

480

153

252

Net cash used in investing activities

-1,335

-1,578

-480

-153

-252

Cash flows from financing activities:
Payment of venture debt issuance costs

-

-

-

23

3

Payment of deferred offering costs

-

-

-

283

1,506

Proceeds from venture debt, net of debt issuance costs of $0 and $50

-

2,728

-

-

-

Proceeds from venture debt, net of debt issuance costs of $50

-

-

10,000

-

-

Proceeds from issuance of debt and warrants, net of debt issuance costs of $0 and $3,073

-

71,927

-

1,333

5,000

Payment of principal and prepayment penalty on venture debt

-

21,847

1,111

1,333

-

Payment of principal on finance lease

30

-

-

-

-

Proceeds from common stock offerings, net of underwriters' discounts and offering cost

8,425

70,766

94,005

-

-

Proceeds from exercise of warrants

-

-

379

-

-

Proceeds from exercise of stock options and issuance of common stock under employee stock purchase plan

587

530

423

0

104

Net cash provided by financing activities

8,982

124,104

103,696

67,214

10,480

Net increase/(decrease) in cash and restricted cash:

-85,073

68,405

69,118

39,713

-4,861

Reconciliation of cash and restricted cash:
Less restricted cash

-

-

134

109

109

Non-cash investing and financing activities:
Right-of-use asset obtained in exchange for finance lease obligation

136

-

-

-

-

Purchases of property and equipment in accrued expenses

195

-

-

-

-

Purchases of property and equipment in accounts payable

-

155

-

-

-

Cashless exercise of warrants

-

-

411

-

-

Deferred offering costs included in accounts payable and accruals

-

-

-

-

226

Supplemental disclosure:
Fair value of warrants issued in connection with venture debt

-

-

-

225

-

Cash paid for interest

7,522

3,041

863

681

442

Conversion of convertible preferred stock into common stock

-

-

118,391

-

-

Right-of-use assets obtained in exchange of operating lease obligations

1,852

29,427

-

-

-